The current strategy for managing chronic gout is the use of uric-acid-lowering drugs to reduce urate production or of a uricosuric agent to promote renal uric acid excretion. Probenecid is ...

Gout, the clinical manifestation of hyperuricemia ... and research has clearly established that chronic inflammatory diseases such as rheumatoid arthritis and systemic lupus erythematosus are ...

and tolerability of serum uric acid lowering and maintenance with febuxostat in patients with gout. Febuxostat Open-label Clinical Trial of Urate-lowering Efficacy and Safety Adverse events were ...

In some individuals, particularly the elderly, gout episodes become chronic, and crystals of uric acid metabolism byproducts are deposited over the affected joint, forming swellings known as tophi.

Sweden’s Sobi has kicked off a rolling biologics license application in the US for SEL-212, vying to become a new option for patients with refractory chronic gout that doesn’t respond to ...

Uric acid crystals can accumulate under the skin and form lumps called "tophi." Chronic (long-term) gout can cause knee ...

Gout is a painful, debilitating form of arthritis, and while it’s often associated with the Tudors, it still impacts millions ...

This week's topics include the impact of lipoprotein(a), or Lp(a), frailty as a predictor of dementia, a diabetes medicine in kidney stones and gout, and the impact of multiple chronic medical ...

Optimizing urate-lowering therapy to achieve target serum urate levels may not harm, and may benefit, patients with gout and CKD. Despite clinician concerns, treating patients with gout and stage ...

ABP-671 is a class 1 innovative chemotherapeutic drug for the treatment of gout and hyperuricemia, currently in Phase 2b/3 clinical trials for gout in China and overseas. The Product reduces renal ...

Using urate-lowering therapy to reach target urate levels appears safe in patients with chronic kidney disease (CKD).